Table 1. Baseline characteristics of study participants and treatment information.
| Variables | All (n=243) | SOTRs (n=83) | Non-SOTRs (n=160) | P-value | |
|---|---|---|---|---|---|
| Age, years | 60 (51, 66) | 60 (50, 65) | 61 (52, 67) | 0.558 | |
| <50, n (%) | 54 (22.2) | 19 (22.9) | 35 (21.9) | 0.776 | |
| 50–59, n (%) | 60 (24.7) | 21 (25.3) | 39 (24.4) | ||
| 60–69, n (%) | 90 (37.0) | 33 (39.8) | 57 (35.6) | ||
| 70–79, n (%) | 33 (13.6) | 8 (9.6) | 25 (15.6) | ||
| ≥80, n (%) | 6 (2.5) | 2 (2.5) | 4 (2.5) | ||
| Sex, male, n (%) | 178 (73.3) | 62 (74.7) | 116 (72.5) | 0.713 | |
| Body mass index, kg/m2, median (IQR) | 23.0 (20.8, 25.1) | 22.5 (20.3, 24.5) | 23.1 (20.8, 25.6) | 0.591 | |
| Body mass index, >25 kg/m2, n (%) | 61 (25.1) | 17 (20.5) | 44 (27.5) | 0.231 | |
| Vaccination status, n (%) | |||||
| Unvaccinated | 106 (43.6) | 26 (31.3) | 80 (50.0) | 0.005 | |
| One dose | 7 (2.9) | 1 (1.2) | 6 (3.7) | 0.428 | |
| Two doses | 48 (19.8) | 17 (20.5) | 31 (19.4) | 0.837 | |
| Three doses | 82 (33.7) | 39 (47.0) | 43 (26.9) | 0.002 | |
| Disease severity on hospitalization, n (%) | 0.145 | ||||
| Asymptomatic | 21 (8.6) | 3 (3.6) | 18 (11.2) | ||
| Mild | 146 (60.1) | 48 (57.8) | 98 (61.3) | ||
| Moderate | 50 (20.6) | 21 (25.3) | 29 (18.1) | ||
| Severe | 24 (9.9) | 10 (12.0) | 14 (8.7) | ||
| Critical | 2 (0.8) | 1 (1.2) | 1 (0.6) | ||
| Charlson Comorbidity Index score, median (IQR) | 2 (1, 4) | 2 (1, 4) | 2 (0, 3) | 0.528 | |
| Comorbidities, n (%) | |||||
| Congestive heart failure | 5 (2.1) | 1 (1.2) | 4 (2.5) | 0.664 | |
| Chronic obstructive pulmonary disease | 22 (9.1) | 4 (4.8) | 18 (11.2) | 0.098 | |
| Diabetes mellitus | 77 (31.7) | 37 (44.6) | 40 (25.0) | 0.002 | |
| Chronic kidney disease | 36 (14.8) | 26 (31.3) | 10 (6.2) | <0.001 | |
| Transplant organ, n (%) | |||||
| Kidney | 62 (74.7) | ||||
| Liver | 17 (20.5) | ||||
| Heart | 1 (1.2) | ||||
| Othersa | 3 (3.6) | ||||
| Treatment, n (%) | |||||
| Regdanvimab | 84 (34.6) | 21 (25.3) | 63 (39.4) | 0.029 | |
| Remdesivir | 65 (26.7) | 31 (37.3) | 34 (21.2) | 0.007 | |
| Dexamethasone | 58 (23.9) | 26 (31.3) | 32 (20.0) | 0.050 | |
| Length of hospital stay, days, median (IQR) | 8.0 (6.0, 11.0) | 8 (7.0, 12.0) | 8.0 (6.0, 10.0) | 0.166 | |
aTwo patients underwent liver-kidney transplantation, and one underwent kidney-pancreas transplantation.
SOTRs, Solid organ transplant recipients; Non-SOTRs, non-solid organ transplant recipients; IQR, interquartile range.